Medicament composition for treating pulmonary fibrosis

Abstract

The invention provides a medicament composition for treating pulmonary fibrosis. The medicament composition is a preparation prepared from the following active pharmaceutical ingredients by weight: 5-15 parts of ginseng, 7.5-22.5 parts of danshen root, 7.5-22.5 parts of ginkgo leaves, 7.5-22.5 parts of radix asparagi, 7.5-22.5 parts of manyflower solomonseal rhizome, 7.5-22.5 parts of snakegourd peel, 2.5-7.5 parts of angelica and 2.5-7.5 parts of panax notoginseng. The invention also provides a preparation method and application of the medicament composition. The medicament has definite effect, can improve the clinical symptoms and quality of life of the patients with organ fibrosis and has obvious effect.

Description

technical field [0001] The invention relates to a pharmaceutical composition for treating pulmonary fibrosis, which belongs to the field of medicines. Background technique [0002] Pulmonary fibrosis (PF) is a major disease that has received a lot of attention from the international medical community. However, the current treatments are lacklustre and toxic side effects are unavoidable. Therefore, it is imperative to seek new treatments including traditional Chinese medicine and the unique advantages of traditional Chinese medicine. . [0003] Studies at home and abroad believe that: "Fibrosis is the root cause of chronic diseases that cannot be cured for a long time, and it is also the main cause of disability and death. Nearly 50% of deaths are related to fibrosis, and the root cause of various chronic lung diseases is that they have fibrosis. Pathological changes.” PF is the most representative, typical and frequent fibrotic disease in organ fibrosis, and its etiology is...

AI Technical Summary

Problems solved by technology

In terms of treatment, the treatment of pulmonary fibrosis is currently limited to non-specific anti-inflammatory, immunosuppressant and glucocorticoids, and its common feature is the lack of specific treatment, and scholars believe: "A large number of antibiotics and hormones are the cause of tissue and organ fibrosis. The latest research results are gradually revealing that long-term use of hormones and antibiotics to treat pulmonary fibrosis is much more serious than the fibrotic changes caused by the primary disease itself

At present, the international community has realized the seriousness of this problem, and chemical preparations cannot solve the problem of severe side effects.”